Company: MDCXW
Filing Date: 2025-06-13
Form Type: PRE 14A
Source: 0001062993-25-011673
Chunk: 36

Company: Medicus Pharma Ltd.
Filing Date: 2025-06-13
Form: PRE 14A
Chunk 36
---
 matter in which directors or officers may have a conflict.

<div align='center'>- 28 -</div>

THE BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE "" THE ELECTION OF THE NOMINEES IN PROPOSAL 2.

<div align='center'>PROPOSAL 3 - QUORUM AMENDMENT</div>

The Company ceased to be a foreign private issuer under U.S. securities laws as of January 1, 2025. The corporate governance rules of Nasdaq (the "Nasdaq Rules") require the Company, having ceased to be a foreign private issuer, to have a quorum requirement for the transaction of business at a meeting of Shareholders of not less than 33⅓% of the outstanding shares of a Company's common voting stock.

On May 6, 2025, the Board approved an amendment to Article 3.2 of the Company's by-laws to replace the reference to "10%" with a reference to "33⅓%" (the "Quorum Amendment") to comply with the Nasdaq Rules.

After giving effect to the Quorum Amendment, the full text of Section 3.2 of the Company's by-laws is as follows:

3.2 Quorum at Meetings of Shareholders

A quorum for the transaction of business at any meeting of shareholders shall be 2 voting persons holding or representing in the aggregate not less than 33⅓% of the issued and outstanding shares of the Company, or of the class or classes respectively (if there is more than one class of shares outstanding for the time being). Notwithstanding the foregoing, if the Company has only one shareholder, or only one shareholder of any class or series of shares, the shareholder present in person or by proxy constitutes a meeting and a quorum for such meeting.

In accordance with Section 116(2) of the OBCA, the Quorum Amendment is hereby submitted for confirmation by the Shareholders of the Company.

The Board recommends that Shareholders vote in favor of the following by-law resolution at the Meeting (the "By-Law Resolution").

"RESOLVED, as an ordinary resolution of the shareholders of Medicus Pharma Ltd., that:

(a)the amendment of By-Law No. 1, such that Article 3.2 of By-Law No. 1 is in the form attached hereto as Schedule "A", is hereby confirmed, ratified and approved;

(b)any director or officer of the Company be and he